Kazuomi Ueshima

5PUBLICATIONS
41CO-AUTHORS
Biomedical imagingPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Mar 21, 2026
Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd-EOB-DTPA-MRI.

Tomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima

|Jan 25, 2026
Impact of Early-Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti-VEGF Agents.

Naoshi Nishida, Kazuomi Ueshima, Tomoko Aoki

|Nov 03, 2025
Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT.

Kazuomi Ueshima, Kaoru Tsuchiya, Tatsuya Yamashita

|Mar 07, 2025
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.

Tomoko Aoki, Masatoshi Kudo, Naoshi Nishida

|Feb 24, 2023
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines).

Kiyoshi Hasegawa, Nobuyuki Takemura, Tatsuya Yamashita

Pageof 1

Frequent Collaborators

4 joint publications

Masatoshi Kudo

3 joint publications

Tomoko Aoki

2 joint publications

Atsushi Naganuma

2 joint publications

Toru Ishikawa